NYXH Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

1.820

Open

1.810

VWAP

1.70

Vol

540.31K

Mkt Cap

168.12M

Low

1.600

Amount

918.52K

EV/EBITDA(TTM)

--

Total Shares

100.07M

EV

168.23M

EV/OCF(TTM)

--

P/S(TTM)

4.08

Nyxoah SA is a Belgium-based company that produces medical equipment. The company focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.

Show More

Events Timeline

(ET)

2026-07-07

16:30:00

Nyxoah Reports Over 20% Sequential U.S. Revenue Growth in Q2

2026-07-07

16:30:00

Company Expects 2026 Global Net Revenue of EUR 36M to EUR 40M

2026-06-05 (ET)

2026-06-05

11:40:00

Nyxoah Plans to Close Offering Around June 9

2026-06-05

10:00:00

Nyxoah S.A. Trading Halted, News Pending

2026-06-04 (ET)

2026-06-04

16:10:00

Nyxoah SA Launches Underwritten Public Offering in the U.S.

2026-06-04

16:10:00

Nyxoah Initiates Leadership Transition, Searching for U.S.-Based CEO

2026-05-12 (ET)

2026-05-12

17:10:00

Nyxoah Reports Q1 Revenue of €6.37M

News

seekingalpha

07-07seekingalpha

Nyxoah SA Reports 21% Revenue Growth in Q2 2026

Newsfilter

06-30Newsfilter

Nyxoah SA Voting Rights and Share Information Released

Newsfilter

06-29Newsfilter

Nyxoah Receives Transparency Notifications from Major Shareholders

Newsfilter

06-19Newsfilter

Nyxoah Invites Shareholders to Extraordinary Meeting on July 9, 2026

Newsfilter

06-10Newsfilter

Nyxoah Discloses Voting Rights and Share Information

Newsfilter

06-10Newsfilter

Nyxoah Secures $110 Million Financing to Accelerate U.S. Launch

5 Analyst Rating

Wall Street analysts forecast NYXH stock price to rise

4 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

5.82

Averages

10.41

High

13.00

Current: 0.000

Low

5.82

Averages

10.41

High

13.00

Stifel

Hold

downgrade

$5 -> $3

AI Analysis

2026-06-17

Reason

Stifel

Price Target

$5 -> $3

AI Analysis

2026-06-17

downgrade

Hold

Reason

Stifel lowered the firm's price target on Nyxoah to $3 from $5 and keeps a Hold rating on the shares after updating the firm's model for the company's recent capital raise.

Piper Sandler

Overweight

downgrade

$9 -> $7

2026-05-13

Reason

Piper Sandler

Price Target

$9 -> $7

2026-05-13

downgrade

Overweight

Reason

Piper Sandler lowered the firm's price target on Nyxoah to $7 from $9 and keeps an Overweight rating on the shares following quarterly results. Genio launch appears to be progressing well with U.S. net-revenue up 25% quarter-over-quarter and consistent with company expectations, the firm notes. Piper continues to believe Nyxoah has the potential to become a high-growth asset, though it acknowledges the balance sheet will likely need to be bolstered some.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NYXH

Unlock Now

Valuation Metrics

The current forward P/E ratio for Nyxoah SA (NYXH.O) is 0.00, compared to its 5-year average forward P/E of -5.12. For a more detailed relative valuation and DCF analysis to assess Nyxoah SA's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-5.12

Current PE

0.00

Overvalued PE

-0.52

Undervalued PE

-9.72

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-3.93

Current EV/EBITDA

-0.83

Overvalued EV/EBITDA

-0.27

Undervalued EV/EBITDA

-7.59

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

27.91

Current PS

2.31

Overvalued PS

52.89

Undervalued PS

2.94

Financials

AI Analysis

Annual

Quarterly

Whales Holding NYXH

Trading Trends

People Also Watch

Frequently Asked Questions

What is Nyxoah SA (NYXH) stock price today?

The current price of NYXH is 1.68 USD — it has decreased -5.08

What is Nyxoah SA (NYXH)'s business?

Nyxoah SA is a Belgium-based company that produces medical equipment. The company focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.

What is the price predicton of NYXH Stock?

Wall Street analysts forecast NYXH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NYXH is10.41 USD with a low forecast of 5.82 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Nyxoah SA (NYXH)'s revenue for the last quarter?

Nyxoah SA revenue for the last quarter amounts to 6.37M USD, increased 498.87

What is Nyxoah SA (NYXH)'s earnings per share (EPS) for the last quarter?

Nyxoah SA. EPS for the last quarter amounts to -0.37 USD, decreased -38.33

How many employees does Nyxoah SA (NYXH). have?

Nyxoah SA (NYXH) has 147 emplpoyees as of July 08 2026.

What is Nyxoah SA (NYXH) market cap?

Today NYXH has the market capitalization of 168.12M USD.